Efficacy and Safety of Burosumab in X-linked Hypophosphatemia
Pooled result · Serum phosphorus (RCTs)Result — go to the resultDifference 0.52 mg/dL 95% CI 0.24–0.80Authors' conclusion
This study suggests that burosumab can be an option for patients with XLH and did not significantly increase the incidence of adverse events.
Study context
- Population
- Patients with X-linked hypophosphatemia (XLH)8 articles: 5 randomized controlled trials (RCTs), 3 single-arm trials (SATs)
- Comparison
- Burosumab vs control
- Outcome
- Serum phosphorus (RCTs)
Pooled result
As reported in the abstract
Difference
0.52 mg/dL
95% CI 0.24–0.80
Burosumabvs Control
difference 0.52 mg/dL (95% CI 0.24–0.80)
Further pooled results
Pooled change in burosumab arms of all trials (RCTs and SATs)
mg/dL
- Serum phosphorus level, significant increase
- 0.78 (95% CI 0.61-0.96 mg/dL)
- TmP/GFR, significant increase
- 0.86 (95% CI 0.60-1.12 mg/dL)
Secondary events
- Changes in secondary events also validated the effects of burosumab treatment
Safety
- RCTs: safety profile of burosumab not much different from control
- SATs: incidence of any treatment emergency adverse event (TEAE) and related TEAE high; most AEs mild to moderate; serious TEAE rate low
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Efficacy and Safety of Burosumab in X-linked Hypophosphatemia. J Clin Endocrinol Metab. Published 27 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →